123 related articles for article (PubMed ID: 38061276)
1. HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma.
Koskela H; Li Y; Joutsiniemi T; Muranen T; Isoviita VM; Huhtinen K; Micoli G; Lavikka K; Marchi G; Hietanen S; Virtanen A; Hautaniemi S; Oikkonen J; Hynninen J
Gynecol Oncol; 2024 Jan; 180():91-98. PubMed ID: 38061276
[TBL] [Abstract][Full Text] [Related]
2. Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes.
Pikkusaari S; Tumiati M; Virtanen A; Oikkonen J; Li Y; Perez-Villatoro F; Muranen T; Salko M; Huhtinen K; Kanerva A; Koskela H; Tapper J; Koivisto-Korander R; Joutsiniemi T; Haltia UM; Lassus H; Hautaniemi S; Färkkilä A; Hynninen J; Hietanen S; Carpén O; Kauppi L
Clin Cancer Res; 2023 Aug; 29(16):3110-3123. PubMed ID: 36805632
[TBL] [Abstract][Full Text] [Related]
3. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis.
Batalini F; DaSilva LL; Campoverde L; Comini ACM; Carvalho BM; Nogueira W; Silveira H; Ernst BJ; Mina LA
Chin Clin Oncol; 2023 Jun; 12(3):21. PubMed ID: 37211773
[TBL] [Abstract][Full Text] [Related]
4. A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis.
Communal L; Roy N; Cahuzac M; Rahimi K; Köbel M; Provencher DM; Mes-Masson AM
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34070214
[TBL] [Abstract][Full Text] [Related]
5. Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma.
Feng Z; Shao D; Cai Y; Bi R; Ju X; Chen D; Song C; Chen X; Li J; An N; Li Y; Zhou Q; Xiu Z; Zhu S; Wu X; Wen H
J Ovarian Res; 2023 Mar; 16(1):53. PubMed ID: 36922847
[TBL] [Abstract][Full Text] [Related]
6. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance.
Cobb LP; Sun CC; Iyer R; Nick AM; Fleming ND; Westin SN; Sood AK; Wong KK; Silva EG; Gershenson DM
Gynecol Oncol; 2020 Sep; 158(3):653-658. PubMed ID: 32709538
[TBL] [Abstract][Full Text] [Related]
7. RAD51/geminin/γH2AX immunohistochemical expression predicts platinum-based chemotherapy response in ovarian high-grade serous carcinoma.
Kim K; Kim SH; Lee JY; Kim YN; Lee ST; Park E
J Gynecol Oncol; 2023 Jul; 34(4):e45. PubMed ID: 36807748
[TBL] [Abstract][Full Text] [Related]
8. Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma.
Chao A; Lai CH; Wang TH; Jung SM; Lee YS; Chang WY; Yang LY; Ku FC; Huang HJ; Chao AS; Wang CJ; Chang TC; Wu RC
J Mol Med (Berl); 2018 Jun; 96(6):527-536. PubMed ID: 29725737
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience.
Chung YS; Lee JY; Kim HS; Nam EJ; Kim SW; Kim YT
Yonsei Med J; 2018 Oct; 59(8):930-936. PubMed ID: 30187699
[TBL] [Abstract][Full Text] [Related]
10. Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2023; 23(5):1-188. PubMed ID: 37637244
[TBL] [Abstract][Full Text] [Related]
11. Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
Cohen PA; Powell A; Böhm S; Gilks CB; Stewart CJR; Meniawy TM; Bulsara M; Avril S; Brockbank EC; Bosse T; de Azevedo Focchi GR; Ganesan R; Glasspool RM; Howitt BE; Kim HS; Lee JY; Le ND; Lockley M; Manchanda R; Mandalia T; McCluggage WG; McNeish I; Midha D; Srinivasan R; Tan YY; van der Griend R; Yunokawa M; Zannoni GF; ; Singh N
Gynecol Oncol; 2019 Aug; 154(2):441-448. PubMed ID: 31118141
[TBL] [Abstract][Full Text] [Related]
12. Comparison of clinical behavior between mucinous ovarian carcinoma with infiltrative and expansile invasion and high-grade serous ovarian carcinoma: a retrospective analysis.
Hada T; Miyamoto M; Ishibashi H; Matsuura H; Kakimoto S; Iwahashi H; Tsuda H; Takano M
Diagn Pathol; 2022 Jan; 17(1):12. PubMed ID: 35057833
[TBL] [Abstract][Full Text] [Related]
13. [Clinicopathological study of SET subtype of ovarian high-grade serous carcinoma].
Sun YW; Shen DH; Cui SS; He HJ; Zhang XL; Wang W; Liu CR
Zhonghua Fu Chan Ke Za Zhi; 2019 Sep; 54(9):595-600. PubMed ID: 31550775
[No Abstract] [Full Text] [Related]
14. LRP1B-a prognostic marker in tubo-ovarian high-grade serous carcinoma.
Kolb S; Hoffmann I; Monjé N; Dragomir MP; Jank P; Bischoff P; Keunecke C; Pohl J; Kunze CA; Marchenko S; Schmitt WD; Kulbe H; Sers C; Sehouli J; Braicu EI; Denkert C; Darb-Esfahani S; Horst D; Sinn BV; Taube ET
Hum Pathol; 2023 Nov; 141():158-168. PubMed ID: 37742945
[TBL] [Abstract][Full Text] [Related]
15. External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma.
Lee JY; Chung YS; Na K; Kim HM; Park CK; Nam EJ; Kim S; Kim SW; Kim YT; Kim HS
J Gynecol Oncol; 2017 Nov; 28(6):e73. PubMed ID: 28758379
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma.
Coghlan E; Meniawy TM; Munro A; Bulsara M; Stewart CJ; Tan A; Koay MHE; MaGee D; Codde J; Tan J; Salfinger SG; Mohan GR; Leung Y; Nichols CB; Cohen PA
Int J Gynecol Cancer; 2017 May; 27(4):708-713. PubMed ID: 28441251
[TBL] [Abstract][Full Text] [Related]
17. MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.
Kang EY; Millstein J; Popovic G; Meagher NS; Bolithon A; Talhouk A; Chiu DS; Anglesio MS; Leung B; Tang K; Lambie N; Pavanello M; Da-Anoy A; Lambrechts D; Loverix L; Olbrecht S; Bisinotto C; Garcia-Donas J; Ruiz-Llorente S; Yagüe-Fernandez M; Edwards RP; Elishaev E; Olawaiye A; Taylor S; Ataseven B; du Bois A; Harter P; Lester J; Høgdall CK; Armasu SM; Huang Y; Vierkant RA; Wang C; Winham SJ; Heublein S; Kommoss FKF; Cramer DW; Sasamoto N; van-Wagensveld L; Lycke M; Mateoiu C; Joseph J; Pike MC; Odunsi K; Tseng CC; Pearce CL; Bilic S; Conrads TP; Hartmann A; Hein A; Jones ME; Leung Y; Beckmann MW; Ruebner M; Schoemaker MJ; Terry KL; El-Bahrawy MA; Coulson P; Etter JL; LaVigne-Mager K; Andress J; Grube M; Fischer A; Neudeck N; Robertson G; Farrell R; Barlow E; Quinn C; Hettiaratchi A; Casablanca Y; Erber R; Stewart CJR; Tan A; Yu Y; Boros J; Brand AH; Harnett PR; Kennedy CJ; Nevins N; Morgan T; Fasching PA; Vergote I; Swerdlow AJ; Candido Dos Reis FJ; Maxwell GL; Neuhausen SL; Barquin-Garcia A; Modugno F; Moysich KB; Crowe PJ; Hirasawa A; Heitz F; Karlan BY; Goode EL; Sinn P; Horlings HM; Høgdall E; Sundfeldt K; Kommoss S; Staebler A; Wu AH; Cohen PA; DeFazio A; Lee CH; Steed H; Le ND; Gayther SA; Lawrenson K; Pharoah PDP; Konecny G; Cook LS; Ramus SJ; Kelemen LE; Köbel M
Virchows Arch; 2022 Apr; 480(4):855-871. PubMed ID: 34782936
[TBL] [Abstract][Full Text] [Related]
18. Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC.
Biacchi D; Accarpio F; Ansaloni L; Macrì A; Ciardi A; Federici O; Spagnoli A; Cavaliere D; Vaira M; Sapienza P; Sammartino P
J Surg Oncol; 2019 Dec; 120(7):1208-1219. PubMed ID: 31531879
[TBL] [Abstract][Full Text] [Related]
19. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
[TBL] [Abstract][Full Text] [Related]
20. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
Patel JN; Braicu I; Timms KM; Solimeno C; Tshiaba P; Reid J; Lanchbury JS; Darb-Esfahani S; Ganapathi MK; Sehouli J; Ganapathi RN
Br J Cancer; 2018 Oct; 119(9):1060-1066. PubMed ID: 30318511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
